What Conditions Is Regenerative Medicine Used For?

As of today, FDA-approved regenerative medicine products are limited to a small, specific list. That list covers two things:

• Cord-blood-derived stem cell products for blood-disorder transplants.
• Since December 2024, one mesenchymal stem cell therapy for a severe pediatric transplant complication (U.S. Food and Drug Administration, 2024).

For joint pain, skin conditions, or aging, everything else marketed as “regenerative medicine” is not FDA-approved. That includes most stem cell, PRP, and exosome offerings. These are either being studied in early-phase research, or used in an investigational, off-label way (U.S. Food and Drug Administration, 2020). That difference is the single most important thing to know before you consider any regenerative option.

What This Means

“Regenerative medicine” is an umbrella term, not a single approved procedure. It covers a range of approaches:

• Platelet-rich plasma (PRP).
• Bone marrow aspirate concentrate.
• Mesenchymal stem cells.
• Exosomes.
• Tissue-engineered products.

These approaches aim to use the body’s own biology, or donor-derived biologic material, to support tissue repair (Sah, 2025). Some have a genuine, FDA-approved track record for a narrow set of blood and immune conditions.

Far more are being researched for orthopedic, dermatologic, and other uses. They have not cleared the same regulatory bar (U.S. Food and Drug Administration, 2020). Hearing “regenerative medicine can help with that” should always prompt a follow-up question. Is this specific product approved for this specific condition? Or is this investigational use?

Candidacy

Candidacy depends on which product and which condition are being discussed. So it has to be judged case by case, not assumed. For the small number of FDA-approved cell therapies, the drug’s own label defines candidacy narrowly. Take the 2024-approved mesenchymal stem cell therapy. It is indicated for steroid-refractory acute graft-versus-host disease in pediatric transplant patients. It is not indicated for general use (U.S. Food and Drug Administration, 2024).

The much larger category is investigational orthopedic, dermatologic, and aesthetic regenerative procedures. Reasonable candidates there are generally adults who have:

• A clearly diagnosed condition.
• Realistic expectations about an unproven or partially proven approach.
• No active infection.
• No uncontrolled autoimmune disease.
• No active malignancy in the area being addressed.

Some people want a guaranteed outcome. Others hope to use a product for one of the many conditions these products are not approved for. The FDA has said so explicitly. Those conditions include orthopedic ones like osteoarthritis. They also include neurological ones like multiple sclerosis or Parkinson’s disease. In either case, they are considering an investigational option, not an approved one (U.S. Food and Drug Administration, 2020).

Clinical Evaluation

A responsible evaluation starts with an accurate diagnosis, not a product pitch. That means:

• A full history.
• A focused physical exam.
• Imaging or lab work, where relevant.

The goal is to confirm what is driving the symptoms. That comes before any regenerative option is discussed. For musculoskeletal complaints, this often includes ultrasound or MRI review to identify the specific structure involved.

Just as important is a candid talk about regulatory status. A patient should be able to ask two things:

• Exactly what product is being proposed.
• Whether it is FDA-approved for their specific condition, or offered as an investigational or off-label option.

And they should get a direct answer (U.S. Food and Drug Administration, 2020). Some clinics gloss over that distinction, or imply broad FDA approval that doesn’t exist. That is a signal to seek a second opinion.

Available Options

Regenerative approaches are one category of option, not the only one. A thorough evaluation should cover the full landscape. For musculoskeletal complaints, that includes:

• Physical therapy.
• Oral or topical anti-inflammatory medication.
• Corticosteroid or other guided injections.
• PRP.
• Surgical evaluation.
• Continued observation.
• Investigational stem cell or exosome options.

Dermatologic uses include hair loss and certain pigmentation disorders. There, regenerative approaches are being studied alongside established topical, laser, and procedural options (Jafarzadeh et al., 2024).

Sometimes an FDA-approved regenerative product genuinely exists for a narrow condition. There, the comparison point is usually alternatives from standard transplant and hematology care. A specialist in that field should guide that decision, not a general aesthetics or wellness clinic (U.S. Food and Drug Administration, 2024).

Benefits, Limitations & Risks

The proposed benefit across regenerative approaches is that they may support the body’s own repair processes. Laboratory research and early clinical studies in orthopedic and dermatologic uses describe the following (Sah, 2025; Jafarzadeh et al., 2024):

• Cell proliferation.
• Modulation of local inflammation.
• Tissue remodeling.

Where FDA approval exists, controlled trials have shown that benefit for a specific, narrow indication. The MSC therapy approved in 2024 showed a 70% overall response rate at Day 28 in its pivotal trial. That was for its approved use (U.S. Food and Drug Administration, 2024). Where approval does not exist, the same benefit is plausible but unproven for the condition in question.

Limitations and risks are significant, and they are not evenly distributed across products. Most regenerative products used for joint, skin, or anti-aging purposes are not FDA-approved for those uses. So across providers there is no standard for:

• Dosing.
• Manufacturing process.
• Quality benchmark.

Results from one clinic or product do not reliably transfer to another. The FDA has specifically warned about unapproved regenerative products marketed online. They may lack proven clinical benefit. In some cases they have caused serious harm. That includes infection from donor-derived biologic material that was not properly processed and screened (U.S. Food and Drug Administration, 2020).

Relying on an unapproved product has another cost. It can delay a patient from getting an accurate diagnosis. It can also delay an option with a real evidence base for their specific condition (U.S. Food and Drug Administration, 2020).

What the Evidence Shows

Current evidence establishes that regenerative approaches work through biologically plausible mechanisms. Those include cell signaling, modulation of inflammation, and tissue remodeling. That mechanism has translated into genuine, FDA-approved benefit for a small number of specific, well-studied indications. Certain blood and immune conditions are the clearest examples (U.S. Food and Drug Administration, 2024).

Peer-reviewed research also shows encouraging early- and mid-stage results in orthopedic uses. Among several regenerative options studied, mesenchymal stem cell therapy was identified as the most effective option for pain reduction. Dermatologic conditions such as androgenetic alopecia and vitiligo have also been studied. A systematic review of randomized trials covered those conditions. It found improvement rates as high as 68% and 71% respectively (Sah, 2025; Jafarzadeh et al., 2024).

These products are informally marketed for a much broader range of conditions. The evidence does not yet establish that the same encouraging results carry over into FDA-approved options there. Standardization of manufacturing, dosing, and patient selection remains an active area of research. Regulators have been explicit on one point. Approval for one narrow use does not extend to orthopedic, neurological, or cardiovascular conditions. It does not extend to other conditions some providers imply are covered (U.S. Food and Drug Administration, 2020; Sah, 2025).

Recovery / Next Steps

Recovery varies a lot depending on which procedure is involved. “Regenerative medicine” spans everything from an outpatient injection to an inpatient infusion protocol. For injection-based orthopedic or aesthetic procedures, mild soreness or swelling at the site for a few days is typical. Most patients resume normal activity quickly. The FDA-approved MSC infusion therapy is different. Its recommended course involves multiple intravenous infusions over about four weeks. They are given in a monitored clinical setting fit for a serious pediatric transplant complication. That is a very different recovery picture from an office-based joint injection (U.S. Food and Drug Administration, 2024).

In either case, a follow-up evaluation at a sensible interval is part of a reasonable plan. Do not assume improvement, and do not judge results too early.

Orlando Considerations

Florida does not have a separate state licensing category for giving regenerative medicine products. Clinicians who offer these procedures in the Orlando area are still bound by standard Florida medical licensure and scope-of-practice rules. The same federal FDA framework that applies nationwide sits on top of that. A clinic’s location does not change a product’s federal regulatory status (U.S. Food and Drug Administration, 2020). If you are evaluating a local provider, confirm the clinician’s licensure. Then ask the same product-specific approval questions outlined above. Do that regardless of how a practice markets itself locally.

Frequently Asked Questions

Is regenerative medicine FDA-approved for joint pain or arthritis?

No. Stem cell, exosome, and similar products are marketed as regenerative medicine. The FDA has specifically stated that none is approved for any orthopedic condition. That includes osteoarthritis.

What is regenerative medicine actually approved for?

FDA-approved uses are limited to two things right now. First, cord-blood-derived stem cell products for certain blood-disorder transplants. Second, one mesenchymal stem cell therapy approved in December 2024 for a specific severe pediatric transplant complication.

If a clinic offers stem cells for my condition, does that mean it’s approved?

Not necessarily, and often not at all. Many clinics offer investigational or off-label use of regenerative products. That is legal in certain contexts. But it is not the same as FDA approval for that specific condition. Always ask directly.

Is research on regenerative medicine for other conditions still happening?

Yes. Active peer-reviewed research continues in orthopedics, dermatology, neurology, and cardiology. Some early results are encouraging. But promising research is not the same as an approved option.

Most regenerative medicine products used outside their specific FDA-approved indication are investigational and are not FDA-approved to diagnose, cure, mitigate, treat, or prevent any disease or condition beyond their approved label.

This article is for educational purposes only and is not medical advice. Individual results vary, and any decision to pursue a regenerative or aesthetic procedure should be made after a full evaluation with a licensed physician who can review your specific history, alternatives, and risks.

Medically reviewed by Kenny Chantasi, DO.

References

Jafarzadeh, A., Pour Mohammad, A., Keramati, H., Zeinali, R., Khosravi, M., & Goodarzi, A. (2024). Regenerative medicine in the management of specific dermatologic disorders: A systematic review of randomized controlled clinical trials. Stem Cell Research & Therapy, 15, 182. https://doi.org/10.1186/s13287-024-03800-6

Mayo Clinic News Network. (2024, October 16). Diverse ways regenerative medicine is advancing health care. https://newsnetwork.mayoclinic.org/discussion/diverse-ways-regenerative-medicine-is-advancing-health-care/

Sah, A. K. (2025). Advances in regenerative medicine for orthopedic injuries: A comprehensive review. Cureus, 17(2), e79860. https://doi.org/10.7759/cureus.79860

U.S. Food and Drug Administration. (2020, July 22). Consumer alert on regenerative medicine products including stem cells and exosomes. https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes

U.S. Food and Drug Administration. (2024, December 18). FDA approves remestemcel-L-rknd for steroid-refractory acute graft versus host disease in pediatric patients. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-remestemcel-l-rknd-steroid-refractory-acute-graft-versus-host-disease-pediatric

Last medically reviewed: August 26, 2026.

Related reading

• What Is Regenerative Medicine Used For?
• Is Stem Cell Therapy Legal in the U.S.?
• How Do You Know If You’re a Good Candidate for Regenerative Medicine?

More questions answered on the PrimeCell patient blog, or see frequently asked questions.

Related services at PrimeCell

PrimeCell is a physician-led practice in Orlando. Candidacy for any procedure is determined at an in-person evaluation.